RESUMO
Background: Leukopenia is one of the side effects of radiotherapy and chemotherapy. Diyushengbai tablet (DYT) is used to prevent and treat leukopenia caused by various reasons. A meta-analysis was performed to systematically analyze the therapeutic effects of DYT on preventing and treating leukopenia caused by radiotherapy and chemotherapy. Objectives: This study aimed to systematically evaluate the efficacy and safety of DYT in preventing and treating leukopenia caused by radiotherapy and chemotherapy. Methods: We performed a comprehensive literature search of electronic databases such as PubMed, The Cochrane Library, China Knowledge Network (CNKI), China Biomedical Literature Database (CBM), Wanfang Data Knowledge Service Platform, and VIP, through November of 2021. The scanning reports deadline is until November 2021. The bias risk evaluation criteria developed by the Cochrane collaborative organization were used to evaluate the literature quality of the included studies. The RevMan5.4 software was used to analyze the data, and the Stata16.0 was used to perform the Egger test. Results: After selecting all the databases, a total of 41 reports which involved 3,793 cases were analyzed. Meta-analysis showed that DYT could significantly reduce the white blood cell (WBC) suppression caused by radiotherapy and chemotherapy and improve the patients' WBC counts and neutrophils, compared with the efficacy of other oral WBC-elevating drugs such as Leucogen tablets and Batilol tablets and additional utilization of granulocyte colony-stimulating factor (G-CSF). The results of meta-analysis showed that for preventive medication purpose, the overall incidence of leukocyte suppression was [RR = 0.74, 95%CI (0.59, 0.92), p = 0.006], and the white blood cell count was [MD = 1.12, 95%CI (0.95, 1.29), p < 0.00001]; while for therapeutic purpose, the incidence of overall leukocyte suppression was [RR = 0.61, 95%CI (0.38, 0.95), p = 0.03], and the white blood cell count was [MD = 1.20, 95%CI (0.77, 1.62), p < 0.00001]. More importantly, the additional use of DYT can reduce the application amount of G-CSF. The results showed that the application of G-CSF can be reduced by an average of 1.57 from the beginning of treatment to return normal white blood cells around 2.23 in two cycles of chemotherapy. Conclusion: DYT is more effective in preventing and treating leukopenia caused by radiotherapy and chemotherapy than other oral WBC-elevating drugs, which have a high clinical value.
RESUMO
Background: Depression is a common mental disorder, and its morbidity rate is expected to rank second among all mental disorders by 2020. Hence, traditional Chinese medicines gradually attract the attention of many researchers because of their various targets and low toxicity. Huolisu oral solution (HLS) is a Chinese medicine compound preparation, which is present in the Chinese Pharmacopoeia. It is used clinically mainly for the treatment of neurasthenia, perimenopausal syndrome, and insomnia, or depression associated with cerebrovascular disease. Despite the fact that HLS has been used as an antidepressant in clinics, the underlying mechanism is still an untouched domain. To provide a theoretical basis for the clinical application, a series of assessment methods, such as the tail suspension test (TST), forced swim test (FST), and locomotor activity test in mice and rat models of chronic unpredictable mild stress (CUMS), have been conducted in our study. Objective: The aim of the study was to explore the antidepressive effect and mechanism of HLS. Methods: CUMS was induced in rats to simulate a depression-like behavior. Neurotransmitters and hormones were detected by enzyme-link immunosorbent assay (ELISA). Pathomorphology examination of the hippocampus was obtained by using the TSView 7 image analysis system. The active ingredients of HLS were also determined by high-performance liquid chromatography (HPLC). Results: HLS could alleviate the depression-like behavior of the model rats. Biochemical analysis showed that HLS enhanced the levels of 5-hydroxytryptamine (5-HT), norepinephrine (NE), and dopamine (DA) in the hippocampus and diminished these in the serum of the CUMS rats. HLS could also decrease the concentration of corticosterone (CORT), adrenocorticotropic hormone (ACTH), and ß-endorphin (ß-EP) in blood. The pathohistological examination revealed that the hippocampus and adrenal gland were improved after treatment with HLS. Conclusions: This study concluded that HLS could alleviate depression-like behaviors in the rats exposed to CUMS, and the potential mechanism may be related to the regulation of the monoamine neurotransmitters, the hypothalamic-pituitary-adrenal (HPA) axis, and the ß-EP. These findings hint that HLS is likely to be a potentially effective agent for treating depression.
RESUMO
BACKGROUND: This study aimed to investigate the anti-tumor effects of Huisheng Oral Solution (HSOS) on the promotion of blood circulation to dispel blood stasis, the inhibition of metastasis and inflammation, the pathogenesis of tumor progression, and to provide guidelines for using HSOS in clinical settings. METHODS: Eight-month-old Lewis lung carcinoma (LLC)-bearing C57BL/6 mice were orally administered HSOS (0.25 mL/d) for 21 d starting on day 2 of model generation. One hour after the final administration, their eyeballs were dissected out to collect serum to determine tissue factor (TF) and interleukin-6 (IL-6) levels via ELISA. Blood was collected intracardially with an anticoagulant to determine fibrinogen levels, using an automated blood coagulation analyzer. The mice were euthanized via cervical dislocation and their thymi, spleens, and tumors were extracted for weight measurement and organ index calculation. CD44 and MMP2 expression and VEGF protein and mRNA expression in tumor tissues were detected using immunohistochemical (IHC) and RT-qPCR assays, respectively. Lastly, the effect of HSOS on the migration ability of A549 lung carcinoma cells was investigated using in vitro scratch assay. RESULTS: HSOS significantly downregulated TF and Fib in tumor-bearing mice. HSOS inhibited the overexpression of CD44, MMP2, and VEGF, and the migration ability of tumor cells. Moreover, the pro-inflammatory cytokine (IL-6) was significantly downregulated, but the thymic and splenic indices increased. CONCLUSIONS: HSOS might exert anti-tumor effects by improving hypercoagulability in tumor-bearing mice, inhibiting tumor cell metastasis, alleviating inflammatory responses, and enhancing immune function.